The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for the first generic raltegravir medicines, designed to treat adult and pediatric HIV patients weighing at least 40 kg. This approval marks a significant step forward in the availability of affordable HIV treatment options.The new marketing authorization for generic raltegravir was granted to […]
New data presented by Gilead Sciences, Inc. has highlighted the efficacy, safety, and patient tolerability of Sunlenca (lenacapavir), the first long-acting injectable HIV treatment administered twice yearly. The data came from the Phase 2/3 CAPELLA trial, including patient-reported outcomes (PRO), demonstrating lenacapavir’s potential in transforming HIV clinical care. The findings were unveiled at the 12th […]
Rukobia FDA approval : ViiV Healthcare said that the US Food and Drug Administration (FDA) has approved Rukobia (fostemsavir), 600 mg extended-release tablets as a new treatment of HIV patients having limited treatment options. According to the FDA, Rukobia is a new type of antiretroviral medication for adult HIV patients who tried various HIV medications […]
In the latest pharma industry news, ViiV Healthcare has bagged Juluca FDA approval for the maintenance treatment of virologically suppressed HIV-1 infection.
ViiV Healthcare, a joint venture between GlaxoSmithKline (GSK), Pfizer, and Shionogi, has received approval from the U.S. Food and Drug Administration (FDA) for its two-drug regimen, Juluca, for the maintenance treatment of adults with virologically suppressed human immunodeficiency virus type 1 (HIV-1). This groundbreaking treatment, composed of dolutegravir 50mg and rilpivirine 25mg, is the first […]